 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- BGB-B167 / BeiGene
BGB-B167, a first-in-class 4-1BB (CD137)/ CEACAM5 bispecific antibody, exhibits potent in vitro and in vivo anti-tumor activity and superior safety profile in preclinical models (Section 38) - Mar 5, 2024 - Abstract #AACR2024AACR_3764;
Here, we describe the characterization of BGB-B167 with regard to preclinical proof-of-concept and basic drug-like properties. The combined dataset provides an overview on the design, mode of action, preclinical pharmacology and safety profile of BGB-B167.
- || Tevimbra (tislelizumab) / BeiGene, BGB-B167 / BeiGene
Enrollment closed, Phase classification, Enrollment change, Trial completion date, Combination therapy, Metastases: Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jan 8, 2024
P1, N=55, Active, not recruiting, Sponsor: BeiGene
The combined dataset provides an overview on the design, mode of action, preclinical pharmacology and safety profile of BGB-B167. Recruiting --> Active, not recruiting | Phase classification: P1a/1b --> P1 | N=254 --> 55 | Trial completion date: Aug 2025 --> Jan 2025
- | Tevimbra (tislelizumab) / BeiGene, BGB-B167 / BeiGene
Phase classification, Enrollment change, Trial withdrawal, Combination therapy, Metastases: Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants (clinicaltrials.gov) - Nov 29, 2023
P1, N=0, Withdrawn, Sponsor: BeiGene
Recruiting --> Active, not recruiting | Phase classification: P1a/1b --> P1 | N=254 --> 55 | Trial completion date: Aug 2025 --> Jan 2025 Phase classification: P1a/1b --> P1 | N=254 --> 0 | Not yet recruiting --> Withdrawn
- || Tevimbra (tislelizumab) / BeiGene, BGB-B167 / BeiGene
Trial initiation date, Combination therapy, Metastases: Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants (clinicaltrials.gov) - Oct 12, 2023
P1a/1b, N=254, Not yet recruiting, Sponsor: BeiGene
Phase classification: P1a/1b --> P1 | N=254 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Sep 2023 --> Mar 2024
- || Tevimbra (tislelizumab) / BeiGene, BGB-B167 / BeiGene
Trial initiation date, Combination therapy, Metastases: Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants (clinicaltrials.gov) - Jul 13, 2023
P1a/1b, N=254, Not yet recruiting, Sponsor: BeiGene
Initiation date: Sep 2023 --> Mar 2024 Initiation date: May 2023 --> Sep 2023
- ||| Tevimbra (tislelizumab) / BeiGene, BGB-B167 / BeiGene
New P1 trial, Combination therapy, Metastases: Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants (clinicaltrials.gov) - Dec 9, 2022
P1a/1b, N=254, Not yet recruiting, Sponsor: BeiGene
- ||| Tevimbra (tislelizumab) / BeiGene, BGB-B167 / BeiGene
Enrollment open, Combination therapy, Metastases: Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 26, 2022
P1a/1b, N=254, Recruiting, Sponsor: BeiGene
Initiation date: May 2023 --> Sep 2023 Not yet recruiting --> Recruiting
- ||| Tevimbra (tislelizumab) / BeiGene, BGB-B167 / BeiGene
New P1 trial, Combination therapy, Metastases: Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 10, 2022
P1a/1b, N=254, Not yet recruiting, Sponsor: BeiGene